Related Experiment Video
Updated: May 14, 2026
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
Donor choice according to age for allo-SCT for AML in complete remission
F Ayuk1, T Zabelina, F Wortmann
1Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ayuketan@uke.de
Insights
Younger unrelated donors (UD) significantly improve 5-year overall survival (OS) in acute myeloid leukemia (AML) patients undergoing allogeneic stem cell transplant (allo-SCT) compared to older matched related donors (MRD). Donor age is a critical factor in transplant outcomes.
Area of Science:
- Hematology
- Oncology
- Transplantation Immunology
Background:
- Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative option for acute myeloid leukemia (AML).
- Donor selection is crucial, with age and donor type (unrelated donor [UD] vs. matched related donor [MRD]) being key considerations.
Purpose of the Study:
- To compare the impact of young unrelated donors (UD ≤39 years) versus older matched related donors (MRD >39 years) on 5-year overall survival (OS) in AML patients in complete remission (CR) post-allo-SCT.
- To identify independent prognostic factors for survival in this patient population.
Main Methods:
- Retrospective analysis of 168 AML patients in CR who underwent allo-SCT.
- Kaplan-Meier survival analysis and multivariate analysis were used to assess the impact of donor age and donor type on 5-year OS.
- Donor age cutoff was set at 39 years for young vs. older donors.
Main Results:
- Five-year OS was significantly higher with young UD (≤39 years) compared to older MRD (>39 years) (66% vs. 34%, P=0.001).
- Multivariate analysis identified donor age and cytogenetic risk as independent predictors of 5-year OS.
- Older MRD (>39 years) and older UD (>39 years) were associated with poorer 5-year OS compared to young UD (≤39 years).
- Standard-risk cytogenetics correlated with better 5-year OS than bad-risk cytogenetics.
Conclusions:
- Younger unrelated donors may offer improved outcomes compared to older matched related donors in allo-HSCT for AML.
- Donor age is a significant modifiable factor influencing survival post-allo-SCT for AML.
- Cytogenetic risk remains a critical prognostic indicator in AML patients undergoing transplantation.
Abstract:
In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD ≤39 years vs MRD >39 years (66% vs 34%, P=0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD ≤39 years, both MRD >39 years (relative risk (RR): 4.31, P=0.001) and UD >39 years (RR: 2.14, P=0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P=0.02). Subgroup analyses of patients ≥50 years (n=76) revealed similar results, with 5-yr OS of 62% for UD ≤39 yrs and 26% for MRD >39 yrs (P=0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:28Kidney Transplant I: Introduction